IFF frames Scent's recovery around a rebuilt, stronger R&D pipeline and innovative delivery systems, with Fragrance Ingredients accelerating on higher-value inputs. For H2, Fine Fragrance should see a softer Q3 followed by a stronger Q4, while Consumer Fragrance is expected to grow in the low single digits as R&D and go-to-market efforts support market-share gains—backed by an ongoing 8-9% R&D investment to fuel 2027 growth.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
What are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Management links the Scent recovery to rebuilding the R&D “go-to-market” capability and strengthening the innovation pipeline. They state that 2.5 years ago the R&D pipeline “was not what it should have been,” but today IFF says it has “a very strong R&D capability,” “a great pipeline of molecules as well as delivery systems,” and leading-edge development capability in both Fine Fragrance and Consumer Fragrances 1. This is presented as a foundational driver for regaining market share and improving competitive position 21.
For Fine Fragrance, management attributes near-term performance to active management of Middle East uncertainty/volatility. They say the team “did a very good job at managing the challenges in the Middle East,” finishing Q2 “up slightly positive” versus expectations of “down in Fine Fragrance mid-single digits” coming into the quarter 3. They also explicitly frame the recovery pattern as softer Q3 followed by recovery starting in Q4 3.
For Consumer Fragrance, management expects growth to remain in low single digits in the second half, but emphasizes that the team is working on “rebuild[ing] the R&D capability” and “go-to-market approach with customers” while trying to “drive market share gains” 4. They also cited that Q2 was strong (high single digits) but expects normalization thereafter 4.
Although your question centers on Fine Fragrance and Consumer Fragrance, IFF also points to Fragrance Ingredients as a key near-term driver of Scent performance. In Q2, Scent sales rose 8% 3, and the earnings discussion states a key driver was Fragrance Ingredients growing “north of 20%” 3. Management adds that this benefited from favorable comparisons (prior-year decline “down 10% or more”) and strategic use of synthetics to capture sales amid macro and supply-chain pressures 3. They further clarify that, as conditions settle, the business should normalize toward “higher value-added ingredients versus the traditional synthetics” 3. Separately, management frames the Fragrance Ingredients shift toward “higher-value natural products” as underway, though it “will take a little bit more time” and is more about next year/years after than the current second half 4.
IFF reports Scent segment sales of $665 million, up 8% 5, with EBITDA up 5% to $134 million 5, driven by “volume growth and productivity gains” 5. This provides evidence that the recovery isn’t only sales-based; profitability is improving as well 5.
Management gives a directional “growth-rate by quarter” view rather than exact percentages per quarter, but it is still clear and internally consistent across the excerpts.
Interpretation (from the company’s framing): the recovery is expected to be non-linear—Q3 is pressured by both external volatility and comps, while Q4 shows improvement as volatility eases and the comp becomes less punitive 43.
Interpretation (from the company’s framing): Consumer Fragrance recovery is viewed as more steady and normalization-driven (post-strong Q2), with growth anchored in R&D/customer commercialization and market share gains, rather than a sharp snap-back in one quarter 4.
Management describes a concrete R&D transformation: the pipeline was inadequate 2.5 years ago, and now IFF claims it has “a very strong R&D capability,” “great perfumers” developing “leading-edge new Fine Fragrances and Consumer Fragrances,” and an “excellent pipeline of molecules” and “delivery systems” 1. They explicitly connect this to being optimistic about the future of Scent 1.
Management links forward positioning to where initiatives “will” matter: for Fragrance Ingredients, they say the higher-value natural product shift is underway and “as we go into next year and the year after, we believe we’ll have a really strong competitive position” 4. While this statement is specifically about Fragrance Ingredients, the broader R&D capability discussion in Scent is positioned as enabling leadership in Fine Fragrance and Consumer Fragrance as well 1.
Across Remainco strategy commentary, IFF underscores reinvestment in R&D/innovation to support growth and margin. They refer to R&D spend as being “in that 8% to 9% range” and stress the need to “critically continue to reinvest” because it creates a cycle: investments lead to better growth, which supports margin expansion and enables further reinvestment 6. This is not a numeric 2027 plan by itself, but it is directly stated as a go-forward pillar for Remainco strategy 6, and Scent is explicitly part of that Remainco portfolio 6.
Management says it is “not satisfied,” that they have “strengthen[ed] our strengths and address[ed] our gaps,” and that “a lot more to do” remains—yet progress is “really good” and they are optimistic 1. That matters for 2027 because it implies the R&D plan is iterative and capability-building rather than purely near-term fixes 1.
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
IFF outlines a Scent recovery anchored in disciplined reinvestment in R&D, a strengthened pipeline, and careful navigation of Middle East volatility, with 2H 2026 expected growth in Fine Fragrance and a normalization to low single digits in Consumer Fragrance. The multi-year R&D plan targets 2027 by advancing molecules, delivery systems, and leading‑edge perfumers to sustain competitive advantage.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery hinges on a rebuilt R&D engine, stronger go-to-market execution, and resilient Fine Fragrance performance amid regional volatility. In H2, Fine Fragrance is expected to deliver mid-single-digit growth with a soft Q3 and stronger Q4, while Consumer Fragrance normalizes to low single-digit gains; the company reiterates a 2027-focused plan to sustain innovation through heightened R&D investment and a robust molecule and delivery-systems pipeline.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Q2 2026 discussion frames a Scent recovery driven by a rebuilt R&D pipeline and stronger Consumer Fragrance execution, with Fine Fragrance set for Q4 recovery. The company emphasizes a longer-term R&D and ingredients strategy to support 2027 and beyond.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF’s Scent recovery is anchored in a rebuilt R&D engine, a stronger fragrance ingredients business, and a strategically paced turnaround for Fine and Consumer Fragrances in the second half of 2026. The discussion also highlights ongoing investments in a broader, more innovative product pipeline and a 2027 plan that relies on go-to-market rebuilds and sustained R&D spend to sustain growth and margin expansion.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines that Scent’s rebound rests on a rebuilt R&D engine, a stronger pipeline, and improved go-to-market execution, with Fine Fragrance soft in Q3 and stronger in Q4, and Consumer Fragrance normalizing to low single-digit growth. The plan ties 2027 readiness to sustained R&D investment and closer customer collaboration, while Fragrance Ingredients normalization poses a near-term headwind before a shift to higher-value natural products strengthens longer-term competitiveness.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery is driven by a rebuilt R&D engine and a stronger end-to-end pipeline, including molecules and delivery systems, alongside leading-edge new fragrances. In H2, Fine Fragrance should see softer Q3 and stronger Q4 amid volatility, while Consumer Fragrance normalizes to low single-digit growth as market share gains persist and go-to-market reforms take hold. The 2027 plan centers on sustaining an 8-9% of sales R&D investment and leveraging innovation to fortify competitive positioning.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery led by a strengthened R&D engine, including a pipeline of distinctive molecules and delivery systems, and a go-to-market revival for Consumer Fragrance. Fine Fragrance benefits from improved execution amid Middle East volatility, with an expected Q3 softness and Q4 rebound, while R&D investment positions the company for stronger competitive positioning through 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF maps a resilient Scent recovery driven by Fine Fragrance stabilization, Consumer Fragrance R&D and go-to-market gains, and Fragrance Ingredients momentum, with normalization expected as Scent shifts away from synthetics. For 2H, Fine Fragrance is softer in Q3 and stronger in Q4 (mid-single-digit growth), while Consumer Fragrance should trend to low single digits. The R&D rebuild aims to fortify competitive positioning into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF Scent's recovery hinges on three pillars: Fine Fragrance execution amid Middle East volatility, a Consumer Fragrance strategy built around rebuilding R&D capability and a go-to-market approach to regain market share, and a Fragrance Ingredients tailwind in Q2 that is normalizing as the portfolio shifts toward higher-value ingredients. In H2 2026, Fine Fragrance is expected to maintain mid-single-digit growth while Consumer Fragrance stabilizes at low single-digit, with R&D reinvestment driving a stronger 2027 pipeline.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a science-led recovery for Scent, driven by fragrance ingredients momentum, Fine Fragrance resilience, and a rebuilt Consumer Fragrance GTM with a stronger R&D pipeline. The company expects Q3 softness followed by a stronger Q4 in H2 2026, underpinned by an R&D-led plan for 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a path for Scent recovery anchored in a rebuilt R&D engine and an integrated go-to-market strategy, with Fine Fragrance facing a softer Q3 before a Q4 rebound and Consumer Fragrance expected to normalize to low single-digit growth in 2H 2026. The plan emphasizes higher-value ingredients and sustained R&D investment into 2027 to sustain competitive advantage.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery led by a rebuilt R&D engine, with a stronger pipeline and selective management of Middle East volatility. In 2H, Fine Fragrance is expected to hover in mid-single digits (softer in Q3, stronger in Q4) while Consumer Fragrance should normalize to low single digits as go-to-market and R&D revitalization drive market share. The 2027 plan centers on sustained R&D investment and higher-value natural ingredients.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Dafinchi